ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / ANGO
RCEL (46) SENS (41) SGHT (39) DCTH (62) ⌘ Pro Terminal β†’

AngioDynamics Inc. (ANGO) β€” RQD Stock Rating Cockpit

$11.99 -2.91% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.90

AngioDynamics Inc. (ANGO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (36/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE D- β€’ RED ALERT Cap $519.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ANGO Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ANGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, AngioDynamics Inc. (NASDAQ: ANGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $11.99 (-2.91% 1D, market cap $519.4M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ANGO ranks #632 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ANGO compare to RCEL and SENS in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), ANGO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 54.6%, and ROIC of -23.4%. By comparison, RCEL (Avita Medical Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $516.8M) and SENS (Senseonics Holdings Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $515.5M). Among the 5-stock peer group, ANGO leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ANGO?
β–Ό

Per ANGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001275187), AngioDynamics Inc. generated $320.2M in revenue (+9.5% YoY), -$36.7M in net income, and $508.0K in free cash flow against $269.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $11.90 (-0.71%)🧬 Dilution Drag (+1.92% YoY Shares)βš™οΈ Cash Engine: 10/20 (D) β€’ 0.2% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (36/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510036
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D-
Cash (10)Whales (5)SEC (10)Macro (6)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
$17 Bull$11 Base$8 Bear
πŸ“¬ FREE ANGO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ANGO)Realized 20D OHLCV Swing Band: Β±12.2%
Deterministic 5-Pillar Attribution (36/100 Composite)
πŸ” WHY ANGO SCORES 36/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+10/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0.2% FCF Margin ($508.0K FCF) & 54.6% Gross Margin

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 2.12 (WATCH ZONE (1.8–3.0)) β€’ Piotroski F-Score 6/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
28
Grade E$11.40-0.1% Next Q
Q2 (-2Q)
31
Grade E$11.39+6.8% Next Q
Q3 (-1Q)
33
Grade E$12.17-1.5% Next Q
Current
36
Grade D-$11.99-8.3% Hist 90D Ξ±
Trajectory: E (28) β†’ D- (36)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ANGO Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ANGO currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.12) and Max Pain ($12.59) forces dealer call-delta covering toward $17.10.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANGOβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œANGO Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
44.530 Oversold Β· 70 Hot
ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)
2.12>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
6 / 99-Pt Accounting
52-WEEK LASER RANGE38% OF RANGE
L: $9$11.99H: $16
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ANGO

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (50)

-23.4% ROIC with 54.6% gross margin and 0.10% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 2.12 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (27)

10/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like ANGO
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANGO)

  • βœ“Walkthrough of ANGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ANGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.20%β–Ό DESCENDING CHANNEL
2026-11-02O $12.13H $12.35L $11.99C $11.99VOL 476.2K
RES: $15.67SUP: $10.45SMA50: $14.12SMA200: $12.48
$16.69$15.04$13.40$11.75$10.11RES $15.67SUP $10.45$11.992026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ANGO Butterfly Map β†’ + Track ANGO β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +9.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ANGO today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ANGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ANGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANGO)

Health Care Rank #632 of 1016 βš”οΈ RCEL vs ANGO Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ANGO vs. RCEL, SENS, SGHT, DCTH)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AngioDynamics Inc. (ANGO) ranks #632 by composite RQD confidence (36/100, grade D-) and #441 by equity capitalization ($519.4M). Within this direct 5-issuer industry benchmark cohort, ANGO leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with ANGO at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ANGO ACTIVE
AngioDynamics Inc.
D- 36/100 β€” 54.6% -23.4% -2.91% $519.4M Benchmark Subject
RCEL
Avita Medical Inc.
D 46/100 β€” 82.1% -35.0% -6.34% $516.8M /rcel-vs-ango β†’
SENS
Senseonics Holdings Inc.
D- 41/100 β€” 44.7% -35.0% -2.46% $515.5M /sens-vs-ango β†’
SGHT
Sight Sciences Inc.
D- 39/100 β€” 86.2% -35.0% -2.61% $527.2M /sght-vs-ango β†’
DCTH
Delcath Systems Inc.
C 62/100 β€” 86.2% 0.8% -4.10% $508.0M /dcth-vs-ango β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2026-05-31 β€’ CIK 0001275187

In its most recent audited fiscal period (FY2025, filed 2026-05-31), AngioDynamics Inc. (ANGO) reported GAAP revenue of $320.2M (+9.5% vs. FY2024 revenue of $292.5M , and +5.4% cumulative change since FY2023) , GAAP net income of -$36.7M, operating cash flow of $3.1M, and free cash flow of $508.0K (+103.5% YoY). On the balance sheet, ANGO closed FY2025 with $269.7M in total assets against $0 in total debt (Altman Z-Score: 2.12, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-05-31 $320.2M -$36.7M $3.1M $508.0K $269.7M β€”
FY2024 (FY) 2025-05-31 $292.5M -$34.0M -$10.1M -$14.6M $291.6M β€”
FY2023 (FY) 2024-05-31 $303.9M -$184.3M -$28.2M -$28.2M β€” β€”

3. ANGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, AngioDynamics Inc. (NASDAQ: ANGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $11.99 (-2.91% 1D, market cap $519.4M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ANGO ranks #632 in composite RQD confidence.

How does ANGO compare to RCEL and SENS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), ANGO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 54.6%, and ROIC of -23.4%. By comparison, RCEL (Avita Medical Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $516.8M) and SENS (Senseonics Holdings Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $515.5M). Among the 5-stock peer group, ANGO leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANGO?

Per ANGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001275187), AngioDynamics Inc. generated $320.2M in revenue (+9.5% YoY), -$36.7M in net income, and $508.0K in free cash flow against $269.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANGO trading relative to its 50-day, 200-day, and 52-week technical levels?

ANGO last traded at $11.99 (-2.91% on volume of 475,847 shares), positioning the stock -15.08% below its 50-day simple moving average ($14.12) and -3.93% below its 200-day simple moving average ($12.48). Across its 52-week range of $9.39 to $16.29, ANGO sits at the 37.7% percentile with a 14-day RSI of 44.5 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.2% ($10.53 to $13.45).

ANGO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Should I buy, hold, or sell ANGO stock right now?

AngioDynamics Inc. (ANGO) currently earns a Roarable Rating of D- (Sell β€” SELL) with 36/100 RQD Confidence. Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.

What is ANGO's 12-month price target and RQD AI Jury consensus?

ANGO's 12-month base price target is $10.8 (range $8.42 to $17.1), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ANGO RQD Cockpit ANGO 12M Forecast ANGO Earnings & Move ANGO Dividends & DRIP ANGO Insiders & 13F ANGO Whale Options ANGO Profit Sankey ANGO News & Why
ROARABLE RATING BRIEF β€’ RQD 36/100 (D-) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

ANGO β€” AngioDynamics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:35:28Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ANGO scores 36 out of 100 with a letter grade of D- and a verdict label of "Roarable Sell β€” Vulnerable Balance Sheet & Flow." Across the five pillars, the Fundamental Cash Engine scores 10 of 20 (ROIC of -23.4% and FCF yield of 0.1%), indicating that the business is not currently generating returns on invested capital. Whale/13F Flow scores 5 of 20 and Insider Conviction scores 5 of 20, signaling weak institutional and insider support in the source data; the Butterfly graph and analyst/holder sections contain no further detail on these flows. Macro Regime Fit scores 6 of 20 with a beta of 1.0. Forensic Balance Sheet scores 10 of 20, reflecting an Altman Z-Score of 2.12, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5. For a prospective investor, the upside case rests on a turnaround in operating economics from current negative margins; the valuation tradeoff is that earnings-based multiples are not available in source data, so value cannot be anchored to profitability, and the low FCF yield means little current cash return to shareholders. The balance-sheet metrics provide some staying power, but the combined rating points to elevated fundamental and flow risk.

Business

AngioDynamics Inc. (ANGO) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. Per the profile, the company has a market capitalization of $0.5B. Per the market data, gross margin is 54.6%, indicating that the company retains a substantial share of revenue after direct costs. Not available in source data for product lines, customer segments, or specific revenue-generation mechanics beyond the reported revenue figures.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$320.2M$-39.9M$-36.7MN/A$0.5M$41.6MN/A
FY 2024$292.5M$-40.0M$-34.0MN/A$-14.6M$54.1MN/A
FY 2023$303.9M$-192.4M$-184.3MN/A$-28.2MN/AN/A

Per the SEC financials, revenue rose from $292.5M in FY 2024 to $320.2M in FY 2025, while operating income remained negative in each reported period. Per the market data, operating margin is -12.5%, net margin is -11.5%, and ROIC is -23.4%. Per the Roarable RQD rating, the Altman Z-Score is 2.12 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.5. Cash declined from $54.1M in FY 2024 to $41.6M in FY 2025 per the SEC financials.

Recent Catalysts & News Wire Analysis

  • Market wire (YELLOW): Yahoo Finance UK coverage of ANGO market action, institutional positioning, and fundamental catalysts (1h ago).
  • Risk watch (YELLOW): The Motley Fool, "Why AngioDynamics Crashed Today" (3h ago).
  • Risk watch (RED): Yahoo Finance, "AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates" (6h ago).
  • Market wire (YELLOW): Seeking Alpha, AngioDynamics 2027 Q1 earnings call presentation dated 2026-10-08 (9h ago).
  • Risk watch (RED): Simply Wall St, "AngioDynamics (ANGO) Stock Price Sinks As Losses Cloud Med Tech Progress" (12h ago).
  • Catalyst (GREEN): Investing.com, Canaccord reiterating its stock rating on growth platforms (15h ago).

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The news items carry light classifications of YELLOW, RED, and GREEN as shown; the summaries are generic and do not specify the underlying figures.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, no upstream or downstream dependencies, butterfly links, or proprietary signals are recorded. Sector: Health Care; industry: Medical/Dental Instruments. Not available in source data for sector correlations or 2nd-order bottlenecks. Investors should note that the absence of mapped links is itself a data gap rather than evidence of independence.

Open Questions

  • What drove the negative operating income in each reported period, and what is the trajectory toward profitability?
  • What are the drivers of the cash decline from $54.1M to $41.6M, and what is the company's debt position, given that debt is listed as N/A?
  • Why are EPS and forward/TTM earnings multiples unavailable, and what would a valuation anchored to cash flow or sales look like?
  • What institutional, insider, and options positioning underlies the 5/20 whale and insider pillar scores?
  • What specific catalysts or risks are described in the Q1 loss and earnings-call coverage?

ANGO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AngioDynamics Inc. (ANGO) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ANGO Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ANGO Bull vs. Bear Conversation Board β€” What's Your Call at $11.99?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANGO 🐻 67% BEARISH CONVICTION
1. Pick Your Side on ANGO:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $10.87 (-12.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is ANGO (D- β€’ RQD 36/100) a Buy at $12.35?

Welcome to the ANGO (AngioDynamics Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell β€” Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $9.26 (-25.0%)
Spot @ $12.35

Pump the brakes on ANGO β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ANGO, but look at what you are paying: current EV/EBITDA multiples with 54.6% gross margins. Unless AngioDynamics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $14.57 (+18.0%)
Spot @ $12.35

ANGO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ANGO, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $12.35 (52-wk range $9.39 - $16.29), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%